The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Elsbernd Brian since 2020.
This trader's CIK number is 1763511.
At the time of last reporting, Elsbernd Brian was the Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, Inc.. (stock ticker symbol CPRX).
Also see all insider trading activities at Catalyst Pharmaceuticals, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | CPRX | 0 | $0 | 0 | $0 | 9,667 | $0 |
| 2024 | CPRX | 0 | $0 | 38,256 | $697,515 | 83,401 | $240,600 |
| 2023 | CPRX | 0 | $0 | 50,000 | $803,450 | 66,332 | $56,499 |
| 2022 | CPRX | 0 | $0 | 0 | $0 | 14,667 | $0 |
| 2021 | CPRX | 0 | $0 | 0 | $0 | 14,667 | $0 |
| 2020 | CPRX | 0 | $0 | 0 | $0 | 14,666 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-14 | CPRX | Option Ex | 9,667 | .00 | 0 |
| 2024-12-27 | CPRX | Option Ex | 6,667 | .00 | 0 |
| 2024-12-09 | CPRX | Option Ex | 7,067 | .00 | 0 |
| 2024-11-26 | CPRX | Option Ex | 60,000 | 4.01 | 240,600 |
| 2024-11-26 | CPRX | Sale | 13,256 | 21.61 | 286,515 |
| 2024-03-27 | CPRX | Sale | 25,000 | 16.44 | 411,000 |
| 2024-02-15 | CPRX | Option Ex | 9,667 | .00 | 0 |
| 2023-12-27 | CPRX | Option Ex | 6,666 | .00 | 0 |
| 2023-03-20 | CPRX | Option Ex | 50,000 | 1.13 | 56,499 |
| 2023-03-20 | CPRX | Sale | 50,000 | 16.07 | 803,450 |
| 2023-02-15 | CPRX | Option Ex | 9,666 | .00 | 0 |
| 2022-12-06 | CPRX | Option Ex | 14,667 | .00 | 0 |
| 2021-12-03 | CPRX | Option Ex | 14,667 | .00 | 0 |
| 2020-12-22 | CPRX | Option Ex | 14,666 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Elsbernd Brian (Chief Compliance/Legal Officer of Catalyst Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.